This evidence led to a plethora of preclinical studies in various experimental models of AD, aimed at investigating the effects of specific cannabis extracts, selective CB1/CB2 agonists, or specific inhibitors of eCB metabolic enzymes (as extensively reviewed in references [5,6,7,8]. Here, CNR2 is linked to Alzheimer disease.